Hyaluronate in rheumatology and orthopaedics: Is there a role?

Robin K Strachan, Paul Smith, Dugald L Gardner

The clinical use of connective tissue substitutes is controversial. This viewpoint aims at outlining and highlighting some of the notable work in the field and at encouraging debate.

Hyaluronate is a glycosaminoglycan with a repeating disaccharide structure that is composed of D-glucuronic acid in linkage to N-acetyl-D-glucosamine. Free hyaluronic acid only occurs under laboratory conditions and therefore hyaluronate or hyaluronan are the recommended terms.

Hyaluronate is present in synovial fluid as the major macromolecular component and is responsible for the intrinsic viscoelasticity so characteristic of this fluid. This viscoelasticity is a function of both the concentration and molecular weight of the hyaluronate within synovial fluid. Molecules of 1 x 10^6 molecular weight are formed from 2500 disaccharides and have an extended length of around 2.5 µm. In solution the chain behaves as an expanded random coil with a diameter of 500 nm, with the domain including a large amount of solvent. How the molecules actually behave and interact under physiological conditions in synovial fluid is unclear. They show, however, so-called thixotropic qualities where viscosity or shear resistance falls as shear rate increases.

It has been suggested that the decrease in concentration of hyaluronate is a more important factor in the arthropathies than the observed reduction in molecular weight. High molecular weight hyaluronate in synovial fluid has been shown to be an inhibitor of cellular proliferation. Concentrations of hyaluronate in normal joints range from 1.45 to 2.94 mg/ml in comparison with the protein fraction of 10^4 to 15.8 mg/ml. Hyaluronate filaments are bound to proteoglycans and link proteins to form macromolecular aggregates in cartilage. In weightbearing areas twice as much hyaluronate can be found in the superficial layers of cartilage. Only the 200 nm thick layer, the deeper of two surface layers overlying cartilage zone I, seems to contain hyaluronate. A 50 nm superficial layer on the cartilage surface in close association with the hyaluronate layer seems to be composed of an indeterminate protein complex, which probably includes fibronectin. With age there is a fivefold increase in hyaluronate concentration in the joint articular cartilage, but this is of decreasing molecular weight. Newly synthesised hyaluronate shows little molecular weight change with age, suggesting that some form of extracellular modification or breakdown process is occurring. This leads to a reduction in size of the macromolecular aggregates within the collagen mesh.

A study in which radiolabelled hyaluronate was injected into joints found incorporation of hyaluronate into synovium by two hours and into cartilage by six hours. Menisci did not readily become labelled. Diffusion into cartilage indicated that prior degradation was occurring. Persistence of radioactivity suggested the possibility of resynthesis of degraded hyaluronate by chondrocyte activity. Some of the persistent radioactivity might perhaps be due to reuse of sugars for the synthesis of molecules other than hyaluronate. The autoradiographic patterns, however, were similar to those of other studies showing the incorporation of proline or sulphate into proteoglycans adjacent to chondrocytes.

Cellular effects of hyaluronate

The effect of hyaluronate upon cellular function depends upon concentration, molecular weight, and the cell type in question. Hyaluronate bonded to cell-cell culture substrate inhibits differentiation of myoblasts but stimulates the differentiation of chondroblasts. This chondroblast differentiation is dependent on molecular size, being activated in the molecular weight range 2-4 x 10^5, with no effect at a molecular weight greater than 10^6 kD. The extracellular concentration of hyaluronate regulates the synthesis of proteoglycans during cartilage maturation and in repair processes.

Hyaluronate inhibits the migration of vascular endothelial cells but promotes the migration of other cell types. Oligosaccharides of hyaluronate are angiogenic, however.

Migration of mesenchymal cells in vivo is favoured by matrices abundant in hyaluronate. Leucocyte movement, adhesion, and phagocytosis are all inhibited at high concentrations of hyaluronate, with low concentrations producing stimulation of cell activity, both in vitro and in vivo. High concentrations of hyaluronate can inhibit and low concentrations mediate aggregation in various cell types. Aggregation of virally transformed cells is achieved only at a low concentration of hyaluronate. With high concentrations all of the hyaluronate receptors are assumed to be occupied, leaving no sites available for cross linking of adjacent cells. Cell repulsion due to the charged bulk of hyaluronate might be occurring.
Recent work has provided evidence that hyaluronate acting within the joint can produce analgesia.\textsuperscript{42} Hyaluronidase enhanced sensitivity but hyaluronate reduced pain in the presence of nociceptive agents. Hyaluronate oligosaccharides failed to show any analgesic activity in this model.

**Hyaluronate and rheumatoid arthritis**

During inflammation, such as in the rheumatoid joint, there is a decrease in production, polymerisation, molecular size, and concentration of hyaluronate.\textsuperscript{2,3} The observed depolymerisation of hyaluronate may be mediated by oxygen derived free radicals, generated by inflammatory cells.\textsuperscript{43} Also, lining cells isolated from the rheumatoid joint produce hyaluronate with an unexpectedly low molecular weight.\textsuperscript{44,45} Normal synovial fluid concentrations of hyaluronate seem to have a series of effects upon the inflammatory response.\textsuperscript{46-48} Possibly, removal of the inhibitory effects of 'normal' hyaluronate results in synovial cell hyperplasia, and hyaluronate oligosaccharides may be angiogenic.\textsuperscript{23} Increase of circulating hyaluronate has been found to be significantly higher in rheumatoid patients after physical activity.\textsuperscript{46} Decreased synovial fluid viscosity might possibly accelerate secondary osteoarthritis.

**Hyaluronate and osteoarthritis**

Idiopathic osteoarthritis is characterised by collagen fibre disorganisation, degradation of proteoglycans, and erosion. Physical breakdown of hyaluronate and proteoglycans has been found under conditions of high shear, but these conditions are unlikely to occur regularly within cartilage.\textsuperscript{47} The strength and stiffness of cartilage, osmotic pressure, and the aggregating capacity of the proteoglycans do not show the same degree of reduction with age as the large reduction in aggregate size.\textsuperscript{48,49} Also with age, protein, keratin sulphate, and hyaluronate concentrations are all increased as aggregate size falls, but dissociated proteoglycans form aggregates in direct proportion to hyaluronate concentration.\textsuperscript{49}

It is still thought that aggregate size must be a factor maintaining these molecules within cartilage, however.\textsuperscript{9} The viscosity of aggregates in solution, dependent on shear rate, varies with concentration, but this is not believed to be a contributing factor in aggregate destruction within cartilage.\textsuperscript{50}

Factors playing a part in cartilage degeneration are thought to be chondrocyte proteinase activity and free radical attack, explaining the accumulation of breakdown products related to age. This process might be accelerated during inflammatory episodes.\textsuperscript{51} For technical reasons it has been difficult to determine experimentally the possible participation of hyaluronidase in the development of osteoarthritis.\textsuperscript{9}

**Systemic events**

Studies have found a correlation between serum concentrations of keratan sulphate and hyaluronate and disease severity in osteoarthritis.\textsuperscript{52,53} Other workers have shown partial protective effects of systemic administration of glycosaminoglycans after meniscectomy in a canine model of osteoarthritis.\textsuperscript{54}

Radiolabelled material in the bloodstream after intra-articular injection of hyaluronate suggests that further study of systemic events might assist our understanding of joint physiology.\textsuperscript{12} Apparently, hyaluronate is synthesised in synovium, partly broken down within the joint, and then travels by the lymphatic system to be taken up mainly by lymph nodes where it is degraded. Alternatively, it may continue into the bloodstream to be degraded in the liver, kidney, and spleen. Turnover in the bloodstream is normally in the range of 0.3 to 1.0 g/min/kg body weight, and the half life of free unbound hyaluronate is two days.\textsuperscript{55} On the other hand, as has been previously stated, some molecules within a joint become incorporated into cartilage aggregates.

**Therapeutic effects?**

Is commercially produced hyaluronate an attractive treatment option in osteoarthritis? The serendipitous finding that intra-articular administration of hyaluronate in race horses negated the functional effects of post-traumatic arthritis was an early ‘clinical’ observation.\textsuperscript{56} Cruciate ligament section in dogs induced synovial proliferation and increased production of hyaluronate.\textsuperscript{57} A recent study using the Pond-Nuki experimental model of osteoarthritis in dogs attempted to measure the biochemical and morphological benefits of administration of hyaluronate.\textsuperscript{58,59} Treated joints showed significant reductions in soluble glycosaminoglycans released as a result of the induced joint instability. Cessation of the weekly injections caused a gradual regression in benefit. Inhibition of the development of a ‘fibroblast-like’ layer was found in the treated group and ‘lameness’ was reduced.

**Human clinical therapeutic studies**

A number of studies have now reported clinical improvement after hyaluronate treatment in humans.\textsuperscript{60-66} Variable degrees of pain relief and improved joint function have been recorded. Often, no significant effects were seen in patients with gross morphological changes, but less severe cases showed improvement and the onset of clinical benefit was ‘rapid.’\textsuperscript{66} Other investigators have described longlasting benefit, however, even after withdrawal of treatment.\textsuperscript{64-66}

One recent trial of the intra-articular injection of hyaluronate in osteoarthritis of the knee found significant reduction in pain on movement and at rest, but no marked differences in the activities of daily living.\textsuperscript{57} The regimen consisted of up to 11 injections in 23 weeks. A noteworthy feature of all every study was the lack of serious side effects produced by hundreds of injections. The use of hyaluronate was proposed where other drugs were contraindicated.
Orthopaedic indications?
Excessive use of saline rather than lactate solutions during lengthy arthroscopic procedures can have a deleterious effect upon chondrocyte metabolism. Work still has to be carried out to establish whether other constituents, such as hyaluronate, ought to be incorporated. The anti-inflammatory, analgesic and lubricating properties of hyaluronate suggest the use of hyaluronate as a postoperative instillation.

Other constituents may also be required. They might include the normal glycoprotein fraction, which is apparently necessary to maintain boundary type lubrication at the cartilage surface. This fraction is itself an excellent lubricant.

Reports have described decreases in granulation tissue reaction and scarring, fewer adhesions, and improved tendon healing after the installation of hyaluronate.

The results seem to be an improvement over other materials that act as barriers to fibrinogen and blood cells. Unlike clinical practice, however, some of the experimental models used immobilised tendons after repair.

A recent inquiry reported that a single injection of hyaluronate improved the healing frequency of a partial laceration in the anterior cruciate ligament in the rabbit, and a recent abstract has confirmed reduction of dorsal adhesions in a rabbit model after laminectomy.

The possibilities of using hyaluronate after total joint replacement, nerve repair, tissue resection, trauma, and cartilage repair are subjects for future study.

Conclusions
A recent symposium article described the clinical uses of crosslinked forms of hyaluronate which have been given the generic name of Hylans. The procedures described include so-called 'space-making viscosurgical tools', 'visco-matrix surgical procedures' and 'matrix engineering', 'promotion of tissue regeneration', and 'tissue augmentation'. The nature of these effects has been discussed in this article. There is now enough evidence to stimulate interest in large scale, controlled clinical investigations into the effects of the administration of hyaluronate and other connective tissue substitutes. These trials might also permit evaluation of different regimens, molecular weights, and concentrations of such substitutes.

The continued support of the Arthritis and Rheumatism Council for Research is gratefully acknowledged.


